CN101121696B - Metal salt of pyritinol and hydrate of the same - Google Patents
Metal salt of pyritinol and hydrate of the same Download PDFInfo
- Publication number
- CN101121696B CN101121696B CN2006100696954A CN200610069695A CN101121696B CN 101121696 B CN101121696 B CN 101121696B CN 2006100696954 A CN2006100696954 A CN 2006100696954A CN 200610069695 A CN200610069695 A CN 200610069695A CN 101121696 B CN101121696 B CN 101121696B
- Authority
- CN
- China
- Prior art keywords
- pyritinol
- salt
- injection
- metal
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004986 pyritinol Drugs 0.000 title claims abstract description 57
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 150000003839 salts Chemical class 0.000 title abstract description 4
- 239000002184 metal Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims description 44
- 239000007924 injection Substances 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 16
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 11
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 11
- 159000000000 sodium salts Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 239000000890 drug combination Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 41
- 239000007787 solid Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 26
- 239000007788 liquid Substances 0.000 description 25
- 238000003756 stirring Methods 0.000 description 19
- 239000000843 powder Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 239000011734 sodium Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 206010028851 Necrosis Diseases 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 238000002425 crystallisation Methods 0.000 description 15
- 230000008025 crystallization Effects 0.000 description 15
- 230000017074 necrotic cell death Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- 210000003462 vein Anatomy 0.000 description 14
- 238000005303 weighing Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 11
- 229910052700 potassium Inorganic materials 0.000 description 11
- 239000011591 potassium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 206010020565 Hyperaemia Diseases 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- VFEKMAOUJHONFD-UHFFFAOYSA-N 5-[[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyldisulfanyl]methyl]-4-(hydroxymethyl)-2-methylpyridin-3-ol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO VFEKMAOUJHONFD-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229960000935 dehydrated alcohol Drugs 0.000 description 7
- 210000003725 endotheliocyte Anatomy 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 206010033675 panniculitis Diseases 0.000 description 7
- 229940023488 pill Drugs 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000010025 steaming Methods 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940093181 glucose injection Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 235000019633 pungent taste Nutrition 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000011265 semifinished product Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- -1 absorption carrier Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011082 depyrogenation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OXUMVEOKAMNGER-UHFFFAOYSA-N C.OC=1C=CC=NC1C Chemical compound C.OC=1C=CC=NC1C OXUMVEOKAMNGER-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100696954A CN101121696B (en) | 2006-08-11 | 2006-08-11 | Metal salt of pyritinol and hydrate of the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100696954A CN101121696B (en) | 2006-08-11 | 2006-08-11 | Metal salt of pyritinol and hydrate of the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101121696A CN101121696A (en) | 2008-02-13 |
CN101121696B true CN101121696B (en) | 2010-10-13 |
Family
ID=39084217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100696954A Active CN101121696B (en) | 2006-08-11 | 2006-08-11 | Metal salt of pyritinol and hydrate of the same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101121696B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101373181B (en) | 2007-08-24 | 2012-03-21 | 深圳迈瑞生物医疗电子股份有限公司 | Method and apparatus for calculating point-to-point trace-changing coefficient in real time |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3010966A (en) * | 1958-03-21 | 1961-11-28 | Merck Ag E | Derivatives of vitamin b6 |
CN1491648A (en) * | 2003-09-18 | 2004-04-28 | 伟 熊 | Pyrithioxine hydrochloride freeze-dried power injection and its preparing method |
CN1679565A (en) * | 2004-04-06 | 2005-10-12 | 王玫 | Injection of pyritinol hydrochloride and its preparation |
-
2006
- 2006-08-11 CN CN2006100696954A patent/CN101121696B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3010966A (en) * | 1958-03-21 | 1961-11-28 | Merck Ag E | Derivatives of vitamin b6 |
CN1491648A (en) * | 2003-09-18 | 2004-04-28 | 伟 熊 | Pyrithioxine hydrochloride freeze-dried power injection and its preparing method |
CN1679565A (en) * | 2004-04-06 | 2005-10-12 | 王玫 | Injection of pyritinol hydrochloride and its preparation |
Non-Patent Citations (4)
Title |
---|
李艳芳 等.盐酸吡硫醇合成工艺的改进.齐鲁药事24 6.2005,24(6),367-368. |
李艳芳等.盐酸吡硫醇合成工艺的改进.齐鲁药事24 6.2005,24(6),367-368. * |
陈文华.盐酸吡硫醇的合成工艺改进.化学试剂27 10.2005,27(10),631-632. |
陈文华.盐酸吡硫醇的合成工艺改进.化学试剂27 10.2005,27(10),631-632. * |
Also Published As
Publication number | Publication date |
---|---|
CN101121696A (en) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160110369A (en) | Drug combination, method of preparing same, and use thereof | |
CN107693515B (en) | Pharmaceutical composition containing alkalizer and eltrombopag and application thereof | |
CN100584835C (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
CN101121696B (en) | Metal salt of pyritinol and hydrate of the same | |
KR101740163B1 (en) | Use of 3-n-butyl-1-isoindolinone in preparation of drugs for preventing and treating cerebral infarction | |
CN101195582A (en) | Cinnamic amide derivant | |
CN103980279B (en) | A kind of methotrexate compound and methotrexate for injection | |
CN104138376A (en) | A sustained release agent improving anoxia endurance | |
CN103191051B (en) | Nelarabine injection composition and preparation method thereof | |
CN100509787C (en) | New pharmaceutically acceptable salt of pyritinol, and a preparation method thereof | |
CN105902564B (en) | A kind of pharmaceutical composition and preparation method for treating hypertension | |
CN115124420B (en) | Rhein and matrine eutectic hydrate, preparation method, composition and application thereof | |
CN104086490A (en) | Glipizide compound as well as pharmaceutical composition containing glipizide compound and preparation method of glipizide compound | |
CN104069063A (en) | Hydroxyfasudil pharmaceutical composition and preparation method thereof | |
CN103070842B (en) | Preparation method of miglitol sustained release tablet | |
CN100526293C (en) | 2,5-dihydroxy benzenes sulfonic acid magnesium and hydrate thereof | |
CN112137965A (en) | Cefaclor particle pharmaceutical composition | |
CN104758273A (en) | Urea micro-capsule preparation and preparation method thereof | |
CN107868009A (en) | A kind of metoprolol tartrate crystal and the pharmaceutical composition containing the crystal and preparation method thereof | |
CN101019837B (en) | Ginnone ester dispersing table and its preparation method | |
CN101143846B (en) | Metal salt of quinaprilat | |
CN104814933A (en) | Gardenia extract freeze-dried powder injection and preparation method thereof | |
CN103432086A (en) | Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof | |
CN103833650A (en) | Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient | |
CN100534978C (en) | New medicinal compound salt of 2,5-dihydroxy benzenes sulfonic acid and hydrate thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080523 Address after: Tianchen Avenue in Ji'nan high tech Development Zone in Shandong City, No. 2518, block A Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone in Shandong City, No. 2518, block A Applicant before: Huang Zhenhua |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170815 Address after: Tianchen Avenue high tech Zone of Ji'nan City, Shandong Province, No. 2518 250101 Co-patentee after: Langfang high Bojing State Pharmaceutical Co. Ltd. Patentee after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 block A Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190611 Address after: 101113 Room 301, Building 3, East of Qishanzhuang Village, Zhangjiawan Town, Tongzhou District, Beijing (in Beijing Sihuan Pharmaceutical Co., Ltd.) Co-patentee after: Langfang high Bojing State Pharmaceutical Co. Ltd. Patentee after: Beijing Aohe Pharmaceutical Research Institute Co., Ltd. Address before: 250101 No. 2518 Tianchen Street, Jinan High-tech Zone, Shandong Province Co-patentee before: Langfang high Bojing State Pharmaceutical Co. Ltd. Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210722 Address after: 135000 1688 Wutong Road, Meihekou, Tonghua, Jilin Patentee after: JILIN JINSHENG PHARMACEUTICAL Co.,Ltd. Address before: 101113 Room 301, Building 3, East of Qishanzhuang Village, Zhangjiawan Town, Tongzhou District, Beijing (in Beijing Sihuan Pharmaceutical Co., Ltd.) Patentee before: Beijing Aohe Pharmaceutical Research Institute Co.,Ltd. Patentee before: Langfang high Bojing State Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |